Massachusetts Financial Services Co. MA Increases Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Massachusetts Financial Services Co. MA lifted its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 37.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 323,900 shares of the medical equipment provider's stock after purchasing an additional 87,412 shares during the quarter. Massachusetts Financial Services Co. MA owned about 0.47% of Lantheus worth $28,976,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in shares of Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock worth $184,798,000 after acquiring an additional 32,551 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Lantheus by 47.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider's stock worth $1,041,000 after purchasing an additional 3,772 shares during the last quarter. Empirical Asset Management LLC acquired a new stake in Lantheus during the fourth quarter worth about $323,000. Focus Financial Network Inc. acquired a new position in Lantheus in the 4th quarter valued at about $292,000. Finally, Harbor Capital Advisors Inc. boosted its holdings in Lantheus by 12.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 145,379 shares of the medical equipment provider's stock valued at $13,006,000 after purchasing an additional 16,466 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 64,109 shares of company stock worth $6,110,806. Corporate insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

LNTH has been the topic of several analyst reports. B. Riley reduced their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group began coverage on Lantheus in a report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price target for the company. Finally, Truist Financial boosted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $129.43.

Lantheus Stock Performance

Shares of NASDAQ LNTH traded up $3.49 during trading on Friday, reaching $102.00. The stock had a trading volume of 732,023 shares, compared to its average volume of 955,016. The company has a market cap of $6.98 billion, a P/E ratio of 16.97 and a beta of 0.20. Lantheus Holdings, Inc. has a fifty-two week low of $59.56 and a fifty-two week high of $126.89. The business's 50-day moving average price is $94.00 and its 200-day moving average price is $95.62.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.